- Home
- IMRN
IMRN
Immuron Limited
as 10-28-2025 4:00pm EST
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 14.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 95.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $2.48 | Next Earning Date: | 08-29-2025 |
| Revenue: | $4,777,422 | Revenue Growth: | 48.63% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuron Limited News
IMRN Breaking Stock News: Dive into IMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
Newsfile
11 days ago
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
GlobeNewswire
16 days ago
Immuron Q1 FY26 YoY growth
GlobeNewswire
21 days ago
Immuron Submits IMM-529 IND to FDA
GlobeNewswire
a month ago
Immuron Letter to Shareholders – Projects Update
GlobeNewswire
3 months ago
Immuron - FY25 global sales exceed projection, up 49% on prior year
GlobeNewswire
5 months ago
Immuron Letter to Shareholders: Projects Update
GlobeNewswire
7 months ago
Immuron Travelan® highest sales in history
Compare IMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRN Immuron Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.